GlassScriptPhysician profile
Elizabeth J Overstreet
NPI 1821378894
$716.11
in general payments reported to CMS, 2019-2025
11 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $279 · 2022: $95.51 · 2023: $37.09 · 2024: $65.71 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $128.25 | 2021-2023 | Rybelsus, Ozempic |
| Abbvie INC. | $100.36 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $85.86 | 2021 | |
| Bard Peripheral Vascular, INC. | $77.95 | 2025 | Rotarexs 6 F X 135 Cm |
| Insmed, INC. | $75.80 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.77 | 2021 | |
| Lilly USA, LLC | $48.95 | 2021-2022 | |
| Astellas Pharma US INC | $46.70 | 2024-2025 | Veozah |
| Exeltis, USA INC. | $37.95 | 2024 | Slynd |
| Abbott Laboratories | $24.92 | 2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $16.60 | 2025 | Myfembree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Overstreet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.